For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center...
Important Step Towards Early Detection Of Breast Cancer
5/19/2011
European researchers have developed a clinical PET system with the highest resolution and sensitivity in the market, specifically dedicated to breast cancer detection in early stages. The MAMMI (MAMmography with Molecular Imaging) device will allow doctors to start treatments one or even two years earlier than usual and also evaluate the patient's response to chemotherapy...
YM BioSciences Reports Updated 12-Week Phase I/II Results For Its JAK1/JAK2 Inhibitor CYT387
5/19/2011
YM BioSciences Inc. (NYSE Amex: YMI) (TSX: YM), reported updated interim results for the first 60 patients with high/intermediate-risk myelofibrosis who have completed a minimum of three cycles of treatment (12 weeks) in its ongoing Phase I/II multi-center study...
Roche today announced final results from a randomised, multicentre, double-blind Phase II study with its investigational personalised medicine, MetMAb, in people with previously-treated advanced non-small cell lung cancer (NSCLC). MetMAb is a one-armed investigational antibody designed to target Met, a protein (or receptor) associated with a poor outcome in many cancers...
End-Of-Life Care For Advanced Lung Cancer Differs Markedly Between U.S. And Ontario
5/18/2011
In the United States, older patients with advanced lung cancer make much less use of hospital and emergency room services at the end of life than their counterparts in Ontario but use far more chemotherapy , according to a study published May 18th online in the Journal of the National Cancer Institute. Government-financed health care covers elderly patients in both Canada and the U.S...
Japan, U.S. To Review Pfizer's Fast Track Crizotinib Cancer Treatment
5/18/2011
Confident Pfizer Incorporated announced today that it will submit its new drug crizotinib for approval both to the FDA and the Japanese Ministry of Health, Labor and Welfare (MHLW) after receiving "fast track" status by the FDA in 2010. Crizotinib is the first of its kind of medication intended to treat cellular lung cancer (NSCLC)...
Test Targets Lynch Syndrome, A Risk Factor For Colon Cancer
5/18/2011
Mayo Clinic has developed a screening procedure that could dramatically increase testing for Lynch syndrome, a hereditary genetic disorder that raises cancer risk, particularly for colorectal cancer. An estimated 3 percent of colon cancers can be attributed to Lynch syndrome. At least 80 percent of people with Lynch syndrome develop colorectal cancer, many of them before age 50...
Marker Identifies Breast Cancer Patients Likely To Respond To Tamoxifen
5/18/2011
Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy. The research appears in the May 16 online issue of the Journal of Clinical Oncology...
GTx, Inc. (Nasdaq: GTXI) announced the presentation today of results of a preclinical study demonstrating that Capesaris™ (GTx-758) treatment achieved and maintained castration over the entire 9 month study without evidence of gynecomastia in male cynomolgus monkeys. The data were presented at the Annual Meeting of the American Urological Association...
Micromet, Inc. (Nasdaq: MITI) today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive (MRD) acute lymphoblastic leukemia (ALL) were published in the May 16th on-line edition of the Journal of Clinical Oncology (JCO)...